Publicação
Desenvolvimento de uma imunotoxina baseada no anticorpo Trastuzumab contendo a toxina diftérica (DT) para o tratamento do cancro da mama e carcinoma mamário felino HER2-positivo
| dc.contributor.advisor | Silva,Frederico Nuno Castanheira Aires da | |
| dc.contributor.advisor | Dionísio,Francisco André de Campos Pereira | |
| dc.contributor.author | Silva,Juan José Ribeiro da | |
| dc.contributor.institution | Faculdade de Ciências | |
| dc.date.accessioned | 2026-06-02T16:55:03Z | |
| dc.date.available | 2026-06-02T16:55:03Z | |
| dc.date.issued | 2026 | |
| dc.description | Tese de Mestrado, Microbiologia Aplicada, 2026, Universidade de Lisboa, Faculdade de Ciências | |
| dc.description.abstract | Breast cancer remains one of the leading causes of cancer-related mortality worldwide, with HER2-positive subtypes representing particularly aggressive forms due to their heterogeneity and treatment resistance. Targeted therapies using monoclonal antibodies like Trastuzumab have improved patient outcomes; however, resistance and poor tumour penetration remain significant obstacles. Single-chain variable fragments (scFvs), which retain the antigen-binding regions of antibodies but are smaller in size, offer enhanced tumour penetration and are being explored as alternative therapeutic agents. This study aimed to engineer and characterise a novel recombinant immunotoxin using a microbiology based molecular approach. The therapeutic molecule consists of a fusion between an scFv derived from Trastuzumab (anti-HER2 monoclonal antibody) and the catalytic domain of diphtheria Toxin (DT) from Corynebacterium diphtheriae. The scFv-DT construct was cloned and expressed in Escherichia coli (BL21), enabling large-scale recombinant protein production. Purification was achieved through Immobilized Metal Affinity Chromatography (IMAC), followed by a refolding step via dialysis. In vitro characterisation using ELISA, flow cytometry and immunofluorescence confirmed preserved HER2-specific binding and reactivity in both human breast cancer and feline mammary carcinoma cells. Efficient cellular internalisation was also observed, an essential requirement for DT-mediated citotoxicity. However, cytotoxicity assessment using the WST-1 assay revealed no significant toxic effect, indicating that despite proper binding and internalization, the toxin was not being adequately activated inside the cells. To investigate this, a computational 3D model of the immunotoxin bound to HER2 was generated using AlphaFold and ChimeraX. suggesting possible conformational constraints. In conclusion, this study demonstrates the successful development of a HER2-targeted scFv-DT immunotoxin with strong binding and internalisation. Future studies should focus on linker optimization and genetic modifications to ensure proper intracellular activation of the toxin, paving the way for a more effective therapeutic strategy in both human and veterinary oncology. | en |
| dc.format | application/pdf | |
| dc.identifier.uri | http://hdl.handle.net/10400.5/118913 | |
| dc.language.iso | por | |
| dc.subject | Trastuzumab | |
| dc.subject | immunotoxin | |
| dc.subject | HER2 | |
| dc.subject | diphtheria toxin | |
| dc.title | Desenvolvimento de uma imunotoxina baseada no anticorpo Trastuzumab contendo a toxina diftérica (DT) para o tratamento do cancro da mama e carcinoma mamário felino HER2-positivo | pt |
| dc.type | master thesis | |
| dspace.entity.type | Publication | |
| rcaap.rights | embargoedAccess |
Ficheiros
Principais
1 - 1 de 1
Miniatura indisponível
- Nome:
- TM_Juan_Silva.pdf
- Tamanho:
- 5.54 MB
- Formato:
- Adobe Portable Document Format